title: Therapeutic antibodies in breast cancer.
abstract: The discovery of HER2 and development of trastuzumab pioneered the field of targeted therapy in breast cancer. Hoping to emulate the same clinical success, pharmaceutical companies have developed several antibodies against newly identified membrane-bound targets. Unfortunately, none of these agents has yet matched the thousands of lives saved by trastuzumab. In this article we review the most advanced therapeutic antibodies in breast cancer. While acknowledging their unquestionable benefit, we emphasize the need to better understand their biology and mechanisms of action in order to optimize their use in defined patient populations.
authors.affiliation: Breast Cancer Unit, Vall d׳Hebron Institute of Oncology, Vall d׳Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain.
authors.forename: José
authors.initials: J
authors.lastname: Pérez-Garcia
authors.affiliation: Breast Cancer Unit, Vall d׳Hebron Institute of Oncology, Vall d׳Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain.
authors.forename: Eva
authors.initials: E
authors.lastname: Muñoz-Couselo
authors.affiliation: Breast Cancer Unit, Vall d׳Hebron Institute of Oncology, Vall d׳Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain.
authors.forename: Javier
authors.initials: J
authors.lastname: Cortés
authors.affiliation: Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, NY. Electronic address: scaltrim@mskcc.org.
authors.forename: Maurizio
authors.initials: M
authors.lastname: Scaltriti
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D000951:Antigens, Neoplasm / Q000276:immunology*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000276:immunology*; D005260:Female; D006801:Humans
chemical_list: D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm